For US residents only.

How Treatment May Help

KISQALI + HORMONE THERAPY

Significantly More Effective

The combination of KISQALI® (ribociclib) and letrozole (a type of hormone therapy) was proven to help delay disease progression. KISQALI + letrozole reduced the risk of disease progression by 44% vs letrozole alone. In a clinical trial analysis, more than half of women taking KISQALI + letrozole remained alive and progression free.

KISQALI plus letrozole reduced the risk of disease progression by 44% versus letrozole alone. KISQALI plus letrozole reduced the risk of disease progression by 44% versus letrozole alone.

Shrinks Tumors

KISQALI and letrozole worked together to shrink tumors in women who had measurable tumors. 

52.7% of women with measurable tumors taking KISQALI plus letrozole had tumors that shrank or disappeared 52.7% of women with measurable tumors taking KISQALI plus letrozole had tumors that shrank or disappeared
3 out of 4 women saw tumor shrinkage at the first trial check-in (observed 8 weeks after starting treatment). 3 out of 4 women saw tumor shrinkage at the first trial check-in (observed 8 weeks after starting treatment).

This check-in was not designed to measure tumor size reduction. Based on the design of the trial, this result may not have been caused by the treatment.


*49.6% of women taking KISQALI + letrozole saw their tumors shrink in size vs 34.7% of those taking letrozole alone. And 3.1% of women taking KISQALI + letrozole had their tumors completely disappear vs 2.4% of those taking letrozole alone.